Based on initial trial results, Pfizer’s vaccine candidate for COVID-19 has proven to be 90% effective in fighting the virus. Pfizer and their German partner BioNTech expect a regulatory decision for emergency use authorization as soon as December. The vaccine breakthrough didn’t only shake up the pharmaceutical industry, but the financial sector as well. The S&P and Dow Jones hit record highs, and stocks in numerous world markets soared as well. A potential problem with the vaccine lies in the fact that it needs to be stored in extremely cold temperatures, which may be an out-of-reach infrastructure for lower income countries to obtain financially. The vaccine that has 90% efficacy by Pfizer is delivering 100 million doses to the U.S government beginning this year for distribution.
Read more here.